Sangamo Therapeutics, Inc. (0R1D.L)
USD 0.71
(2.91%)
USD 0.71
(2.91%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -87.42 Million USD | 54.24% |
| 2022 | -189.17 Million USD | -9.79% |
| 2021 | -173.89 Million USD | -41.52% |
| 2020 | -123.87 Million USD | -23.17% |
| 2019 | -101.25 Million USD | -36.33% |
| 2018 | -74.79 Million USD | -36.89% |
| 2017 | -54.86 Million USD | 22.32% |
| 2016 | -70.67 Million USD | -54.86% |
| 2015 | -45.79 Million USD | -78.02% |
| 2014 | -26.23 Million USD | 1.0% |
| 2013 | -26.07 Million USD | -19.77% |
| 2012 | -21.53 Million USD | 38.03% |
| 2011 | -35.1 Million USD | -43.66% |
| 2010 | -24.17 Million USD | -30.56% |
| 2009 | -18.83 Million USD | 19.4% |
| 2008 | -24.85 Million USD | 4.63% |
| 2007 | -24.77 Million USD | -17.29% |
| 2006 | -20.72 Million USD | -68.6% |
| 2005 | -13.26 Million USD | 6.11% |
| 2004 | -13.38 Million USD | -39.18% |
| 2003 | -9.59 Million USD | 10.43% |
| 2002 | -27.88 Million USD | -638.64% |
| 2001 | -11.06 Million USD | 127.49% |
| 2000 | -7.25 Million USD | -126.59% |
| 1999 | -3.2 Million USD | 7.46% |
| 1998 | -3.45 Million USD | -157.1% |
| 1997 | -1.34 Million USD | -322.96% |
| 1996 | -318 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -31.46 Million USD | 25.38% |
| 2024 Q1 | -42.85 Million USD | 22.08% |
| 2023 FY | - USD | 54.24% |
| 2023 Q2 | -14.69 Million USD | -110.44% |
| 2023 Q3 | -16.81 Million USD | -14.38% |
| 2023 Q4 | -59.38 Million USD | -253.25% |
| 2023 Q1 | 140.75 Million USD | 354.11% |
| 2022 Q3 | -54.89 Million USD | -34.77% |
| 2022 FY | - USD | -9.79% |
| 2022 Q1 | -40.32 Million USD | -1.06% |
| 2022 Q2 | -40.73 Million USD | -1.01% |
| 2022 Q4 | -55.39 Million USD | -0.91% |
| 2021 Q2 | -44.41 Million USD | -4.73% |
| 2021 Q1 | -42.4 Million USD | 2.37% |
| 2021 Q4 | -39.89 Million USD | 9.0% |
| 2021 Q3 | -43.84 Million USD | 1.28% |
| 2021 FY | - USD | -41.52% |
| 2020 Q2 | -34.66 Million USD | 16.11% |
| 2020 Q1 | -41.32 Million USD | -2913.14% |
| 2020 Q4 | -43.43 Million USD | -10167.61% |
| 2020 Q3 | -423 Thousand USD | 98.78% |
| 2020 FY | - USD | -23.17% |
| 2019 Q2 | -32.63 Million USD | 24.42% |
| 2019 Q4 | 1.46 Million USD | 105.23% |
| 2019 Q3 | -28.08 Million USD | 13.93% |
| 2019 FY | - USD | -36.33% |
| 2019 Q1 | -43.18 Million USD | -107.89% |
| 2018 Q2 | -18.52 Million USD | 11.79% |
| 2018 Q4 | -20.77 Million USD | -31.63% |
| 2018 FY | - USD | -36.89% |
| 2018 Q1 | -20.99 Million USD | -52.53% |
| 2018 Q3 | -15.78 Million USD | 14.8% |
| 2017 Q1 | -16.49 Million USD | -67.76% |
| 2017 Q2 | -12.45 Million USD | 24.5% |
| 2017 Q3 | -12.62 Million USD | -1.38% |
| 2017 Q4 | -13.76 Million USD | -9.05% |
| 2017 FY | - USD | 22.32% |
| 2016 Q3 | -18.95 Million USD | 29.39% |
| 2016 Q1 | -16.68 Million USD | -6.43% |
| 2016 FY | - USD | -54.86% |
| 2016 Q2 | -26.84 Million USD | -60.91% |
| 2016 Q4 | -9.83 Million USD | 48.14% |
| 2015 Q1 | -6.22 Million USD | -45.72% |
| 2015 Q2 | -11.99 Million USD | -92.83% |
| 2015 FY | - USD | -78.02% |
| 2015 Q3 | -12.68 Million USD | -5.74% |
| 2015 Q4 | -15.67 Million USD | -23.56% |
| 2014 Q2 | -6.98 Million USD | 6.98% |
| 2014 FY | - USD | 1.0% |
| 2014 Q3 | -7.55 Million USD | -8.12% |
| 2014 Q4 | -4.26 Million USD | 43.49% |
| 2014 Q1 | -7.51 Million USD | 6.74% |
| 2013 Q1 | -6.9 Million USD | -104.96% |
| 2013 Q3 | -6.15 Million USD | -12.64% |
| 2013 Q4 | -8.05 Million USD | -30.77% |
| 2013 FY | - USD | -19.77% |
| 2013 Q2 | -5.46 Million USD | 20.81% |
| 2012 Q1 | -7.28 Million USD | -14.42% |
| 2012 Q2 | -5.74 Million USD | 21.13% |
| 2012 Q3 | -5.8 Million USD | -1.01% |
| 2012 Q4 | -3.36 Million USD | 41.93% |
| 2012 FY | - USD | 38.03% |
| 2011 Q1 | -9.43 Million USD | -15.63% |
| 2011 Q2 | -10.28 Million USD | -8.92% |
| 2011 Q3 | -9.57 Million USD | 6.88% |
| 2011 Q4 | -6.36 Million USD | 33.52% |
| 2011 FY | - USD | -43.66% |
| 2010 Q4 | -8.16 Million USD | 6.33% |
| 2010 Q1 | -4 Million USD | -75.42% |
| 2010 FY | - USD | -30.56% |
| 2010 Q2 | -3.87 Million USD | 3.1% |
| 2010 Q3 | -8.71 Million USD | -124.67% |
| 2009 Q4 | -2.28 Million USD | 52.5% |
| 2009 Q2 | -5.15 Million USD | 25.04% |
| 2009 Q1 | -6.88 Million USD | -234.52% |
| 2009 Q3 | -4.8 Million USD | 6.86% |
| 2009 FY | - USD | 19.4% |
| 2008 Q2 | -7.98 Million USD | 9.3% |
| 2008 FY | - USD | 4.63% |
| 2008 Q4 | -2.05 Million USD | 62.39% |
| 2008 Q3 | -5.46 Million USD | 31.54% |
| 2008 Q1 | -8.8 Million USD | -15.79% |
| 2007 Q3 | -5.31 Million USD | 8.89% |
| 2007 Q2 | -5.83 Million USD | 2.81% |
| 2007 Q1 | -6 Million USD | 38.74% |
| 2007 Q4 | -7.6 Million USD | -43.02% |
| 2007 FY | - USD | -17.29% |
| 2006 FY | - USD | -68.6% |
| 2006 Q3 | -3.64 Million USD | 10.54% |
| 2006 Q2 | -4.07 Million USD | -27.89% |
| 2006 Q1 | -3.18 Million USD | -11.8% |
| 2006 Q4 | -9.8 Million USD | -169.17% |
| 2005 Q3 | -3.71 Million USD | -12.33% |
| 2005 Q2 | -3.3 Million USD | 2.36% |
| 2005 Q1 | -3.38 Million USD | -5.81% |
| 2005 FY | - USD | 6.11% |
| 2005 Q4 | -2.84 Million USD | 23.36% |
| 2004 FY | - USD | -39.18% |
| 2004 Q1 | -2.68 Million USD | -431.49% |
| 2004 Q2 | 3.85 Million USD | 243.7% |
| 2004 Q3 | -4.34 Million USD | -212.7% |
| 2004 Q4 | -3.2 Million USD | 26.34% |
| 2003 FY | - USD | 10.43% |
| 2003 Q1 | -2.84 Million USD | -848.16% |
| 2003 Q4 | -505 Thousand USD | 81.71% |
| 2003 Q3 | -2.76 Million USD | 20.87% |
| 2003 Q2 | -3.7 Million USD | -22.72% |
| 2002 Q4 | 448 Thousand USD | 111.74% |
| 2002 FY | - USD | -638.64% |
| 2002 Q3 | -21.06 Million USD | 10.95% |
| 2002 Q2 | -3.63 Million USD | 14.33% |
| 2002 Q1 | -4.43 Million USD | -1363.1% |
| 2001 Q1 | -2.05 Million USD | 2.79% |
| 2001 FY | - USD | 127.49% |
| 2001 Q4 | -290 Thousand USD | -103.66% |
| 2001 Q3 | -5.12 Million USD | 439.2% |
| 2001 Q2 | -2.33 Million USD | -13.65% |
| 2000 Q2 | -1.49 Million USD | 21.3% |
| 2000 Q1 | -1.9 Million USD | 0.0% |
| 2000 FY | - USD | -126.59% |
| 2000 Q4 | -2.11 Million USD | -21.88% |
| 2000 Q3 | -1.73 Million USD | -16.11% |
| 1999 FY | - USD | 7.46% |
| 1998 FY | - USD | -157.1% |
| 1997 FY | - USD | -322.96% |
| 1996 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 100.81% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | 74.693% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 67.132% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 25.689% |
| uniQure N.V. | -253.1 Million USD | 65.458% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 5.052% |
| bluebird bio, Inc. | -167.16 Million USD | 47.699% |
| Imunon, Inc. | -20.78 Million USD | -320.681% |
| Dynavax Technologies Corporation | 9.66 Million USD | 1004.48% |
| Editas Medicine, Inc. | -163.11 Million USD | 46.402% |
| Illumina, Inc. | -608 Million USD | 85.621% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | 80.529% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 102.685% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | 107.511% |
| Myriad Genetics, Inc. | -67.8 Million USD | -28.948% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 121.011% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 80.094% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 188.973% |
| Verastem, Inc. | -83.16 Million USD | -5.123% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 99.225% |
| Waters Corporation | 1.02 Billion USD | 108.552% |
| Biogen Inc. | 2.37 Billion USD | 103.678% |
| Nektar Therapeutics | -243.1 Million USD | 64.038% |
| Perrigo Company plc | 646.2 Million USD | 113.529% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | -96.745% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 15.767% |
| Unity Biotechnology, Inc. | -37.28 Million USD | -134.496% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 128.176% |
| Evolus, Inc. | -41.81 Million USD | -109.105% |
| Adicet Bio, Inc. | -136.53 Million USD | 35.967% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | 0.634% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 101.878% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 41.757% |
| FibroGen, Inc. | -261.4 Million USD | 66.555% |
| Agilent Technologies, Inc. | 1.67 Billion USD | 105.213% |
| OPKO Health, Inc. | -65.51 Million USD | -33.444% |
| Homology Medicines, Inc. | -47.75 Million USD | -83.07% |
| Geron Corporation | -174.78 Million USD | 49.979% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | 61.675% |
| Exelixis, Inc. | 196.6 Million USD | 144.469% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 13.29% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -56.803% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 82.733% |
| Zoetis Inc. | 3.68 Billion USD | 102.373% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 61.142% |
| Abeona Therapeutics Inc. | -50.57 Million USD | -72.876% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 101.898% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | -142.301% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 61.99% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 180.709% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 119.345% |
| Blueprint Medicines Corporation | -474.61 Million USD | 81.579% |
| Insmed Incorporated | -654.73 Million USD | 86.647% |
| TG Therapeutics, Inc. | 26.1 Million USD | 434.969% |
| Incyte Corporation | 919.42 Million USD | 109.509% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 82.698% |